U.S. public companies and their latest annual financials
Every company with a stock ticker that files with the U.S. SEC, with its exchange and latest annual revenue, net income, operating income, diluted EPS, assets, liabilities, equity and cash from its XBRL filings. One row per company.
Columns
Stable keys — use them in the API, SQL and code
| Key | Name | Type | Description |
|---|---|---|---|
| cik | CIK | integer | SEC Central Index Key, the company's permanent EDGAR identifier. |
| name | Company | string | Company name as listed in the SEC ticker file. |
| ticker | Ticker | string | Primary trading symbol. |
| other_tickers | Other tickers | string | Other symbols for the same company, such as other share classes or preferred shares. |
| exchange | Exchange | string | Exchange where the primary ticker trades (Nasdaq, NYSE, CBOE, OTC…), per the SEC ticker file. |
| revenue_usd | Revenue | number · USD | Total revenue for the fiscal year, as tagged in the company's annual XBRL financial statements. |
| net_income_usd | Net income | number · USD | Net income (loss) attributable to the parent company for the fiscal year; negative means a loss. |
| operating_income_usd | Operating income | number · USD | Operating income (loss) for the fiscal year; many banks and insurers do not report this line. |
| eps_diluted_usd | Diluted EPS | number · USD per share | Diluted earnings per share for the fiscal year. |
| total_assets_usd | Total assets | number · USD | Total assets on the balance sheet at fiscal year-end. |
| total_liabilities_usd | Total liabilities | number · USD | Total liabilities at fiscal year-end; empty when the company does not report a total-liabilities line. |
| stockholders_equity_usd | Stockholders' equity | number · USD | Equity attributable to the parent company's shareholders at fiscal year-end (excludes non-controlling interests). |
| cash_usd | Cash & equivalents | number · USD | Cash and cash equivalents on the balance sheet at fiscal year-end (excludes restricted cash). |
| fiscal_year_end | Fiscal year end | date | Last day of the fiscal year the figures cover. |
| fiscal_year_start | Fiscal year start | date | First day of the fiscal year the figures cover. |
| calendar_year | SEC calendar frame | year | Calendar year of the SEC XBRL frame the figures come from (the calendar year that best overlaps the fiscal year). |
| revenue_concept | Revenue XBRL element | string | US-GAAP element used for revenue (e.g. Revenues, RevenueFromContractWithCustomerExcludingAssessedTax). |
| filing_url | Source filing | url | EDGAR folder of the filing that reported the net income (or revenue) figure. |
| edgar_url | EDGAR | url | The company's 10-K filings on SEC EDGAR. |
More in Companies
Highest-grossing films of all time
Films that have earned at least US$500 million at the worldwide box office (not adjusted for inflation), with release year and director. One row per film.
FDA drug approvals: original NDAs and BLAs
Every original New Drug Application (NDA) and Biologics License Application (BLA) approval recorded in the FDA's Drugs@FDA database, with brand name, active ingredients, sponsor, approval date and FDA chemical type. One row per approved application; new molecular entities are flagged.
Largest U.S.-listed companies by revenue
The 500 SEC-reporting companies with a stock ticker that have the highest revenue in their latest annual report, with net income, assets and other key financials. One row per company, ranked by revenue.
Largest companies by number of employees
Companies with at least 100,000 employees according to their most recent headcount in Wikidata, with country, industry, founding year, CEO and stock listing. One row per company.
Billionaires with a net worth over $10 billion
Living people whose most recent net worth recorded in Wikidata is at least US$10 billion, with the date of that estimate, citizenship, main companies and date of birth. One row per person.
FDA drug approvals per year
Number of original New Drug Application (NDA) and Biologics License Application (BLA) approvals the FDA granted each year, and how many were new molecular entities, counted from Drugs@FDA. One row per calendar year.